STOCK TITAN

ElectroCore Inc - ECOR STOCK NEWS

Welcome to our dedicated news page for ElectroCore (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on ElectroCore.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ElectroCore's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ElectroCore's position in the market.

Rhea-AI Summary
electroCore, Inc. expects to report record revenue of approximately $3.55 million for Q2 2023, a 65% increase compared to Q2 2022. Revenue from the government channel is expected to grow by 75% to $2.08 million, while revenue from cash pay channels is expected to grow by 32% to $430,000. Truvaga net revenue is expected to be $291,000, and TAC-STIM revenue is expected to be $311,000. Revenue from outside of the U.S. is expected to decrease by 8%. The Company's net cash used during the quarter was approximately $3.5 million. The Company reiterates its revenue guidance of $14.0-$15.0 million for FY 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.35%
Tags
none
-
Rhea-AI Summary
electroCore's TAC-STIM nVNS Human Performance product has been chosen for the Air Force Research Laboratories (AFRL) A2PEX Grant Program. The goal of A2PEX is to build a wearable system to assess and augment cognitive performance in extreme environments. electroCore's TAC-STIM nVNS will be integrated into the A2PEX system to mitigate fatigue and improve performance. The Air Force has identified the need for novel materials and wearable devices to enhance Airman cognitive performance in aerospace environments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.77%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
ElectroCore Inc

Nasdaq:ECOR

ECOR Rankings

ECOR Stock Data

34.46M
4.17M
18.51%
16.59%
0.17%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
United States
Rockaway

About ECOR

electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.